Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accumulated Expenses: 2013-2021

Historic Accumulated Expenses for Fortress Biotech (FBIO) over the last 9 years, with Sep 2021 value amounting to $82.9 million.

  • Fortress Biotech's Accumulated Expenses rose 292.08% to $82.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $82.9 million, marking a year-over-year increase of 292.08%. This contributed to the annual value of $45.4 million for FY2020, which is 78.70% up from last year.
  • As of Q3 2021, Fortress Biotech's Accumulated Expenses stood at $82.9 million, which was up 38.31% from $59.9 million recorded in Q2 2021.
  • Fortress Biotech's Accumulated Expenses' 5-year high stood at $82.9 million during Q3 2021, with a 5-year trough of $1.0 million in Q3 2019.
  • Moreover, its 3-year median value for Accumulated Expenses was $25.4 million (2019), whereas its average is $31.4 million.
  • Per our database at Business Quant, Fortress Biotech's Accumulated Expenses tumbled by 94.90% in 2019 and then skyrocketed by 1,933.88% in 2020.
  • Over the past 5 years, Fortress Biotech's Accumulated Expenses (Quarterly) stood at $17.6 million in 2017, then decreased by 7.21% to $16.4 million in 2018, then spiked by 55.25% to $25.4 million in 2019, then surged by 78.70% to $45.4 million in 2020, then surged by 292.08% to $82.9 million in 2021.
  • Its Accumulated Expenses stands at $82.9 million for Q3 2021, versus $59.9 million for Q2 2021 and $27.8 million for Q1 2021.